J3M-MC-JZQB CN 4+

Medable, Inc.

Designed for iPhone

    • Free

iPhone Screenshots

Description

Study for patients with KRAS G12C-Mutant, Metastatic Non-Small Cell Lung Cancer

A Multicenter, Randomized, Phase 3 Study Comparing LY3537982 and Pembrolizumab to Placebo and Pembrolizumab as First-Line Treatment in Patients with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer with High PD-L1 Expression (TPS ≥ 50%). This app is specifically intended for participants in the J3M-MC-JZQB study only.

App Privacy

The developer, Medable, Inc., indicated that the app’s privacy practices may include handling of data as described below. For more information, see the developer’s privacy policy.

Data Linked to You

The following data may be collected and linked to your identity:

  • Health & Fitness
  • Identifiers
  • Diagnostics

Privacy practices may vary, for example, based on the features you use or your age. Learn More

More By This Developer

Healthy Oregon Project
Health & Fitness
Medable
Medical
Medable TeleVisit
Medical
Avanti Patient App
Health & Fitness
Option VMS
Health & Fitness
W8M-MC-GN01
Health & Fitness